Avidity
Rachel Johns is the Executive Director of Analytics, Formulations, and QC at Avidity Biosciences, Inc. Rachel has a background in bioengineering with a Ph.D. from the University of Washington. Rachel has extensive experience in research and development, specializing in siRNA delivery systems and formulation development. Prior to their current role, Rachel held various positions at Marina Biotech and PATH, where Rachel optimized amplification of HIV gene and developed assays for low-resource settings. Throughout their career, Rachel has demonstrated strong leadership skills, managing research groups and mentoring students.
This person is not in any teams
Avidity
2 followers
Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.